| Term 
 | Definition 
 
        | 
   A.   Uses                    arthritis   ulcerative colitis         asthma   dermatological conditions   rhinitis    ophthalmic conditions   cancer   lupus erythematosus  infections    organ transplantation trauma    shock             |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
    1. Corticosteroids bind to glucocorticoid or   mineralocorticoid   receptors, the steroid-receptor   complex then regulates gene transcription. 
  
2. Example for anti-inflammatory properties:     glucocorticoids increase lipocortin transcription ↓
  lipocortin inhibits phospholipase A2 ↓
 decreased arachidonic acid and eicosanoids                    |  | 
        |  | 
        
        | Term 
 
        |       Brief Overview of Physiology |  | Definition 
 
        | 
 Glucocorticoid physiology: Increase blood glucose Fat redistribution and lipolysis   Mineralocorticoid physiology: 
  Increase sodium reabsorption    Increase potassium excretion     
 
 |  | 
        |  | 
        
        | Term 
 
        |        Structure-Activity Relationship (SAR) |  | Definition 
 
        | 
 1. Required for activity: ketone at 3 position;      4=5 double bond           2. Small modifications in the basic corticosteroid structure alter:     a.   carbohydrate-potency   b.   sodium-retaining potency   c.   antiinflammatory potency   d.   drug half-life    e.  transcortin binding  |  | 
        |  | 
        
        | Term 
 
        | 
 
 
 Relative potencies of some corticosteroids  (relative to hydrocortisone/cortisol) 
 |  | Definition 
 
        | 
 D.Relative potencies of some corticosteroids  (relative to hydrocortisone/cortisol)     1. Glucocorticoid potencies       Very High:   dexamethasone ,methylprenisolone  triamcinolone   High: Prendisone 
 Very Low: fludrocortisone, betamethasone         2. Mineralocorticoid potencies      Very High:  Fludrocortisone    High: Prednisolone , Methylprensiolone   Very Low: dexamethasone, triamcinolone, betamethasone   |  | 
        |  | 
        
        | Term 
 
        |       Pharmacokinetics : Route of Administration  |  | Definition 
 
        | 
 1.   Routes of administration   Systemic     a.   oral (systemic, long-term therapy)     b.  i.m. or  i.v. (emergency)   Local     c.   topical (eyes and skin)   d.   intra-articular injection (arthritic joints)     e.   inhalation (asthma)   d.   nosespray (rhinitis) |  | 
        |  | 
        
        | Term 
 
        | 
 
 
   Corticosteroid metabolism (liver) |  | Definition 
 
        | 
   a.  reduction of double bond at 4=5 position to yield   inactive metabolite   b.  conjugation of inactive metabolite    c.   excretion         Liver disease affects steroid metabolism.      prednisone--------> prednisolone    (inactive)       (active) |  | 
        |  | 
        
        | Term 
 
        | 
 
    Half-lives of some corticosteroids   |  | Definition 
 
        | Short Acting(8-12 hrs): Hydrocortisone, Cortisone 
 Intermediate Acting(12-36): prednisolone, prendisone,triamcinolone, methylprednisolone   fludrocortisone   Long Acting (36-54) : betamethasone, dexamethasone |  | 
        |  | 
        
        | Term 
 
        |       Side Effects and Toxicity |  | Definition 
 
        | 
   1.   General considerations   a.  route of administration: systemic vs. local   b.   dosage   c.   length of therapy      2.    Short-term systemic  a.   no serious side-effects |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
   a.   Cushingoid features (fat redistribution)   b.   sodium retention (edema, heart failure, hypertension)   c.   potassium loss (muscle weakness)   d.   glucose intolerance (glycosuria/overt diabetes mellitus)    e.   weight gain   f.    loss of skin collagen   g.   osteoporosis*   h.   peptic ulcers   i.    HPA axis suppression   j.    CNS effects (psychosis, insomnia, nervousness, euphoria,   depression)   k.   susceptibility to infection   l.    triamcinolone-weight loss and sedation   m.  masking of symptoms of other diseases |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
   a. inhaled steroids- candidal infection of the mouth,       throat irritation, dysphonia       b. nasal steroids -nasal irritation, headache, dry       nose, nosebleed         c. topical- epidermal atrophy |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
 a. use smallest acceptable dose       b. goal is palliative therapy not total remission      c.  shortest possible therapy (fewer side effects)       d. alternate day therapy for long-term administration   (intermediate-acting, 2X daily dose every other day in AM)     e. administer locally if possible |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
     G. Glucocorticoid Withdrawal      1. General considerations     a. dose   b. treatment length   c. steroid half-life  
         2. Withdrawal protocol      a. use short or intermediating-acting steroids    b. gradually taper dose (over several months)     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
 
a. acute adrenal insufficiency   (1-2 wks, lasts up to 1 yr, individual specific)     b. physical dependence   (fever, malaise, myalgia, fatigue, restlessness)     c. psychological dependence     d. exacerbation of underlying disease  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
     1. Drugs that decrease steroid effectiveness     a.  hepatic enzyme inducers    b.  cholestyramine         2. Drugs that increase steroid effectiveness     a. certain antibiotics (erythromycin)   b. oral contraceptives   c. ketoconazole  |  | 
        |  | 
        
        | Term 
 
        |       
 Drugs affected by steroid administration 
 
 |  | Definition 
 
        |          a. anticoagulants (dosage increase needed)          b. antihypertensives (dosage increase needed)          c. hypoglycemics (dosage increase needed)          d. sympathomimetics (dosage decrease needed)   |  | 
        |  |